RT Journal Article
SR Electronic
T1 Factors associated with COVID-19 susceptibility and severity in patients with multiple sclerosis: A systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.11.21258765
DO 10.1101/2021.06.11.21258765
A1 Barzegar, Mahdi
A1 bagherieh, Sara
A1 Houshi, Shakiba
A1 Hashemi, Mozhgan Sadat
A1 Pishgahi, Ghasem
A1 Afshari-Safavi, Alireza
A1 Mirmosayyeb, Omid
A1 Shaygannejad, Vahid
A1 Zabeti, Aram
YR 2021
UL http://medrxiv.org/content/early/2021/06/15/2021.06.11.21258765.abstract
AB Background We conducted this systematic review to identify factors associated with coronavirus disease (COVID-19) susceptibility and outcomes among people with multiple sclerosis (MS).Methods Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature including reference list and conference abstracts were searched from December 1, 2019, through April 12, 2021. We included cross-sectional, case-control, and cohort studies that reported risk factors of contracting COVID-19 or its outcome in patients with MS on univariate or multivariate regression analyses.Results Out of the initial 2719 records and 1553 conference abstracts, a total of 20 studies were included. Factors associated with COVID-19 susceptibility were reported in 11 studies and risk factors for infection outcomes were discussed in 10. History of contact with an infected is strongly suggested as a risk factor for COVID-19 susceptibility. Other factors that could be associated with contracting infection are younger age, relapsing course, and anti-CD20 agents. The evidence suggests that increasing age, greater MS severity, treatment with anti-CD20 agents, previous use of corticosteroids, and specific comorbidities (obesity and coronary artery disease) could be independently associated with worse infection outcomes. Male sex is likely to be a risk factor for more severe disease. The black or African American race was reported as a possible risk factor.Conclusion Due to a paucity of research and methodological issues, no risk factors for COVID-19 susceptibility and outcomes neither be confirmed nor excluded. Further large studies are needed to address factors associated with COVID-19 susceptibility and severity.Competing Interest StatementAram Zabeti reports compensation for lectures given for Biogen, Genzyme, Novartis, Genentech and ACORDA. Others report no conflict of interest. Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is systematic review. It does not need ethical approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors